

## DAFTAR PUSTAKA

- Abe, T., Seo, T., Ishitsu, T., Nakagawa, T., Hori, M., Nakagawa, K. 2008. Association between *SCN1A* polymorphism and carbamazepine-resistant epilepsy. *Br J Clin Pharmacol* 66: 304–307.
- Abo El Fotoh, W.M., Abd El Naby, S.A., Habib, M.S., Alrefai, A.A., Kasemy, Z.A. 2016. The potential implication of *SCN1A* and *CYP3A5* genetic variants on antiepileptic drug resistance among Egyptian epileptic children. *Seizure* 41:75–80.
- Aerts, J., Wetzels, Y., Cohen, N., Aerssens, J. 2002. Data mining of public SNP databases for the selection of intragenic SNPs. *Hum Mutat* 20:162–173.
- Agresti, A. 1996. *An Introduction to Categorical Data Analysis*, Wiley & Sons, New York.
- Ahn, J.E., Cloyd, J.C., Brundage, R.C., Marino, S.E., Conway, J.M., Ramsay, R.E., White, J.R., Musib, L.C., Rarick, J.O., Birnbaum, A.K. and Leppik, I.E., 2008. Phenytoin half-life and clearance during maintenance therapy in adults and elderly patients with epilepsy. *Neurology*, 71(1), pp.38-43.
- Aicardi J, Shorvon SD. 1997. *Intractable epilepsy*. In: Engel J, Pedley TA, editors. *Epilepsy: a comprehensive textbook*. Philadelphia: Lippincott-Raven; pp. 1325–1331.
- Alekov, A., Rahman, M.M., Mitrovic, N., Lehmann-Horn, F., Lerche, H. 2000. A sodium channel mutation causing epilepsy in Sodium channel *SCN1A* and *SCN2A* in epilepsy man exhibits subtle defects in fast inactivation and activation *in vitro*. *J Physiol* 529: 533–539.
- Allon, N., Woody, C.D. 1983. Epileptiform activity induced in single cells of the sensorimotor cortex of the cat by intracellularly applied scorpion venom. *Exp Neurol* 80:491–497.
- Alzheimer, C., Schwindt, P.C., Crill, W.E. 1993. Modal gating of  $\text{Na}^+$  channels as a mechanism of persistent  $\text{Na}^+$  current in pyramidal neurons from rat and cat sensorimotor cortex. *J Neurosci* 13: 660-673.
- Angelopoulou, C., Veletza, S., Heliopoulos, I., Vadikolias, K., Tripsianis, G., Stathi, C., Piperidou C. 2017. Association of *SCN1A* gene polymorphism with antiepileptic drug responsiveness in the population of Thrace, Greece. *Arch Med Sci* 1: 138–147.
- Armstrong, C.M., Bezanilla, F. 1974. Charge movement associated with the

- opening and closing of the activation gates of Na channels. *J Gen Physiol* 63:533-552.
- Armstrong, C.M., Bezanilla, F. 1973. Currents related to the movement of the gating particles of the sodium channels. *Nature* 242: 459-461.
- Armijo, J.A., Shushtarian, M., Valdizan, E.M., Cuadrado, A., Cuevas, I., Adin, J. 2005. Ion channels and epilepsy. *Curr Pharm* 11:1975-2003.
- Asadi- Pooya, A.A., Emami, M., Ashjazadeh, N., Nikseresht, A., Shariat, A., Petramfar, P. 2013. Reasons for uncontrolled seizures in adults; the impact of pseudointractability. *Seizure* 22: 271- 274.
- Baghel, R., Grover, S., Kaur, H., Jajodia, A., Rawat, C., Srivastava, A., *et al.*, 2016. Evaluating the role of genetic variants on first-line antiepileptic drug response in North India: significance of SCN1A and GABRA1 gene variants in phenytoin monotherapy and its serum drug levels. *CNS Neurosci Ther* 22(9): 740–757.
- Balan, S, Vellichirammal, N.N., Banerjee, M., Radhakrishnan, K. 2012. Failure to find association between febrile seizures and SCN1A rs3812718 polymorphism in south Indian patients with mesial temporal lobe epilepsy and hippocampal sclerosis. *Epilepsy Res* 101:288–92.
- Bao, Y., Liu, X., Xiao, Z. 2018. Association between two SCN1A polymorphisms and resistance to sodium channel blocking AEDs: a meta-analysis. *Neurol Sci* 39(6): 1065–1072.
- Baum, L., Haerian, B.S., Ng, H.K. 2014. Case-control association study of polymorphisms in the voltage-gated sodium channel genes SCN1A, SCN2A, SCN3A, SCN1B, and SCN2B and epilepsy. *Hum Genet* 133: 651-659.
- Baxter, K., 2008. *Stockley's Drug Interactions 8th edition*. Pharmaceutical Press, London UK, pp. 1–3.
- Beani, L., Frey, H., Janz, D. 1985. *Handbook of experimental pharmacology*. Berlin: Springer.
- Beghi, E., Perucca, E. 1995. The Management of Epilepsy in the 1990s: Acquisitions, Uncertainties and Priorities for Future Research. *Drugs* 49: 680-694.
- Beghi, E., Di Mascio, R. and Tognoni, G. 1986. Drug Treatment of Epilepsy: Outlines, Criticism and Perspectives. *Drugs* 31, 249-265.
- Bender, R.A., Soleymani, S.V., Brewster, A.L., Nguyen, S.T., Beck, H, Mathern, G.W. 2003. Enhanced expression of a specific hyperpolarization-activated cyclic

- nucleotide-gated cation channel (HCN) in surviving dentate gyrus granule cells of human and experimental epileptic hippocampus. *J Neurosci* 23: 6826–6836.
- Ben-Ari, Y., Crepel, V., Represa, A. 2008. Seizures Beget Seizures in Temporal Lobe Epilepsies: The Boomerang Effects of Newly Formed Aberrant Kainatergic Synapses. *Epilepsy Curr* 8 (3): 63-72.
- Berg, A.T., Shinnar, S., Levy, S.R., Testa, F.M., Smith-Rapaport, S., Beckerman, B. 2001. Early development of intractable epilepsy in children: a prospective study. *Neurol* 56: 1445–1452.
- Bernard, C., Anderson, A., Becker, A., Poolos, N.P., Beck, H., Johnston, D. 2004. Acquired dendritic channelopathy in temporal lobe epilepsy. *Science* 305: 532–535.
- Berg A.T. 2001. Early development of intractable epilepsy in children: a prospective study. *Neurology* 56:1445–52.
- Bernadino, M.R. Funayama, C. Hamad, A.P. Machado, H. Sakamoto, A. Thome, U. Terra, V.C. Santos, A.C. 2016. Refractory epilepsy in children with brain tumors. The urgency of neurosurgery. *Arq Neuropsiquiatr* 74 (12): 1008-1013.
- Bethmann, K., Fritschy, J.M., Brandt, C., Loscher, W. 2008. Antiepileptic drug resistant rats differ from drug responsive rats in GABA A receptor subunit expression in a model of temporal lobe epilepsy. *Neurobiol Dis* 31:169-187.
- Bhat, M.A, Guru, S.A., Mir, R., Waza, A.A., Zuberi, M., Sumi, M., *et al.*, 2018. Role of SCN1A and SCN2A Gene Polymorphisms in Epilepsy Syndromes-A Study from India. *J Neurol Neurosci* 9(1): 1-11.
- Blair, R.D. 2012. Temporal lobe epilepsy semiology. *Epilepsy Res Treat* 2012:751510.
- Bourgeois, B.F. 1988. Combination of valproate and ethosux- imide: antiepileptic and neurotoxic interaction. *J Pharmacol Exp Ther* 247(3):1128-1132.
- Brodie, M.J., Barry, S.J.E., Bamagous, G.A., Norrie, J.D., Kwan, P. 2012. Patterns of treatment response in newly diagnosed epilepsy. *Neurology* 78: 1548-1554.
- Brodie, M.J., Graeme, J.S. 2011. Combining Antiepileptic Drug-Rationale Polytherapy. *Seizure* 20:369-375.
- Brodie, M.J. 2016. Pharmacological treatment of drug-resistant epilepsy in adults: a practical guide. *Curr Neurol Neurosci Rep* 16(9): 82.
- Brookes, A.J. 1999. The essence of SNPs. *Gene* 234:177–86.

- Brooks- Kayal AR, Shumate MD, Jin H. 1998. Selective changes in single cell GABAA receptor subunit expression and function in temporal lobe epilepsy. *Nat Med* 4: 1166–1172.
- Brown, A.M., Schwindt, P.C., Crill, W.E. 1994. Different voltage dependence of transient and persistent  $\text{Na}^+$  currents is compatible with modal gating hypothesis for sodium channels. *J Neurophysiol* 71: 2562-2565.
- Browne, T.R. 1998. Pharmacokinetics of antiepileptic drugs. *Neurology* 51: S2-7.
- Brugada, J., Brugada, R., Brugada, P. 2007. Channelopathies: a new category of diseases causing sudden death. *Herz* 32:185–191.
- Cantrell, A.R., Catterall, W.A. 2001. Neuromodulation of  $\text{Na}^+$  channels: an unexpected form of cellular plasticity. *Nat Rev Neurosci* 2: 397-407.
- Catterall, W.A. 1999. Molecular properties of brain sodium channels: an important target for anticonvulsant drugs. *Adv Neurol* 79: 441–56.
- Capes, D.L., Goldschen-Ohm, M.P., Arcisio-Miranda, M., Bezanilla, F, Chanda, B. 2013. Domain IV voltage-sensor movement is both sufficient and rate limiting for fast inactivation in sodium channels. *J Gen Physiol* 142:101–112.
- Catterall, W.A., Kalume, F., Oakley, J.C. 2010. Ion channel voltage sensors: structure, function, pathophysiology. *Neuron* 67: 915–928.
- Catterall, W.A. 2012. Voltage-gated sodium channels at 60: structure, function, and pathophysiology. *J Physiol* 1: 2577–2589.
- Chahine, M., Deschenes, I., Trottier, E., Chen, L.Q., Kallen, R.G. 1997. Restoration of fast inactivation in an inactivation-defective human heart sodium channel by the cysteine modifying reagent benzyl-MTS: analysis of IFM-ICM mutation. *Biochem Biophys Res Commun* 233:606–610.
- Chanda, B., Bezanilla, F. 2002. Tracking voltage-dependent conformational changes in skeletal muscle sodium channel during activation. *J Gen Physiol* 120:629–645.
- Chanock, S. 2001. Candidate genes and single nucleotide polymorphisms (SNPs) in the study of human disease. *Dis Markers* 17:89–98.
- Chen, L.Q., Santarelli, V., Horn, R., Kallen, R.G. 1996. A unique role for the S4 segment of domain 4 in the inactivation of sodium channels. *J Gen Physiol* 108:549–556.
- Chen, C., Bharucha, V., Chen, Y., Westenbroek, R.E., Brown, A., Malhotra, J.D.

2002. Reduced sodium channel density, altered voltage dependence of inactivation, and increased susceptibility to seizures in mice lacking sodium channel beta 2-subunits. *Proc Natl Acad Sci* 99:17072–17077.
- Chou, I.C.P.C., Tsai, F.J. 2003. The lack of association between febrile convulsions and polymorphisms in SCN1A. *Epilepsy Res* 54:53- 57.
- Copley, R.R. 2004 Evolutionary convergence of alternative splicing in ion channels. *Trends Genet* 20:171–176.
- Crawford, P. 2005. Best practice guidelines for the management of women with epilepsy. *Epilepsia* 46(Suppl 9): 117-124.
- Crill, W.E. 1996. Persistent sodium current in mammalian central nervous system. *Annu Rev Physiol* 58: 349-362.
- Daci, A., Beretta, G., Vllasaliu, D., Shala, A., Govori, V., Norata, G.D. 2015. Polymorphic variants of SCN1A and EPHX1 influence plasma carbamazepine concentration, metabolism and pharmacoresistance in a population of Kosovar Albanian epileptic patients. *PLoS One* 10 (11), e0142408.
- Dallas, S. , Miller, D.S., Bendayan, R. 2006. Multidrug resistance-associated proteins: expression and function in the central nervous system. *Pharmacol Rev* 58:140–161.
- D’Andrea, G., D’Ambrosio, R.L., Diperna, P., Chetta, M., Santacroce, R., Brancaccio, V., *et al.*, 2005. A polymorphism in the *VKORC1* gene is associated with an interindividual variability in the dose anticoagulant effect of warfarin. *Blood* 105: 645–649.
- Dasgupta, A. 2007. Usefulness of monitoring free (unbound) concentrations of therapeutic drugs in patient management. *Clin Chim Acta* 377:1–13.
- De Vivo, D.C., Leary, D., Wang, D. 2002. Glucose transporter 1 deficiency syndrome and other glycolytic defects. *J Child Neurol* 17 (13): 3S15-23–discussion 3S24-5.
- Dellaportas, C., Marshall, W., Galbraith, A.W., Shorvon, S.D., Reynolds, E.H. 1979. The evolution of chronic toxicity in previously untreated patients on phenytoin or carbamazepine. *Communication to the 11<sup>th</sup> Epilepsy International Symposium*. Florence (In press. 1981)
- Depondt, C., Godard, P., Espel, S., Da Cruz, A.L., Lienard, P., Pandolfo, M. 2011. A candidate gene study of antiepileptic drug tolerability and efficacy identifies an association of CYP2C9 variants with phenytoin toxicity. *Eur J Neurol* 18: 1159–1164.

- Dilantin Product Information (PI). 2018. West Ryde, NSW: Pfizer Australia Pty Ltd. <https://www.ebs.tga.gov.au/ebs/picmi/picmirepository.nsf/pdf?OpenAgent&id=CP-2010-PI-04863-3&d=201907061016933>
- Dlugos, D.J., Buono, R.J., Ferraro, T.N. 2006. Defining the clinical role of pharmacogenetics in antiepileptic drug therapy. *Pharmacogenomics J* 6: 357-359.
- Diss, J.K., Fraser, S.P., Djamgoz, M.B. 2004. Voltage-gated Na<sup>+</sup> channels: multiplicity of expression, plasticity, functional implications and pathophysiological aspects. *Eur Biophys J* 33:180–193.
- Du, Y., Liu, Z., Nomura, Y., Khambay, B., Dong, K. 2006. Alanine in segment 3 of domain III (IIS3) of the cockroach sodium channel contributes to the low pyrethroid sensitivity of an alternative splice variant. *Insect Biochem Mol Biol* 36:161–168.
- Dorman, D.C., Beasley, V.R. 1991. Neurotoxicology of pyrethrin and the pyrethroid insecticides. *Vet Hum Toxicol* 33:23–43.
- Drugs.com. 2022. Prescription Drug Information : Drug Interaction. <http://www.drugs.com>. 28 April 2022
- Eadie, M. I., Tyrer, J. H. 1989. *Anticonvulsant Therapy Pharmacological Basis and Practice*. Churchill Livingstone: Edinburgh.
- Ebers, G.C., George, A.L., Barchi, R.L., Ting-Passador, S.S., Kallen, R.G., Lathrop, G.M., 1991. Paramyotonia congenita and hyperkalemic periodic paralysis are linked to the adult muscle sodium channel gene. *Ann Neurol* 30:810–6.
- Ebrahimi, A., Houshmand, M., Tonekaboni, S.H., Fallah, M.S., Zainali, S., Moghadasi, M. 2010 Two novel mutations in SCN1A gene in Iranian patients with epilepsy. *Arch Med Res* 41(3):207–14.
- Englot, D.J., Berger, M.S., Barbaro, N.M., Chang, E.F. 2011. Predictors of seizure freedom after resection of supratentorial low-grade gliomas. *J Neurosurg* 115: 240-244.
- Ellerkmann, R.K., Riazanski, V., Elger, C.E., 2001. Slow recovery from inactivation regulates the availability of voltage-dependent Na<sup>+</sup> channels in hippocampal granule cells, hilar neurons and basket cells. *J Physiol* 532:385–397.
- Escayg, A., McDonald, B.T., Meisler, M.H., Baulac, S., Huberfeld, G., Gourfinkel,

- I. 2000. Mutations of SCN1A, encoding a neuronal sodium channel, in two families with GEFS+2. *Nat Genet* 24:343–345.
- Featherstone, I.A., Richmond, J. E., Ruben, P. C. 1996. Interaction between fast and slow inactivation in Skm1 sodium channels. *J Biophys* 71: 3098-3109.
- Feldmann, M, Asselin, M.C., Liu, J., Wang, S., McMahon, A., Anton-Rodriguez, J., *et al.*, 2013. P-glycoprotein expression and function in patients with temporal lobe epilepsy: a case-control study. *Lancet Neurol* 12(8):777–85.
- Fisher, R.S., Acevedo, C., Arzimanoglou, A., Bogacz, A., Cross, J.H., Elger, C.E. 2014. ILAE official report: a practical clinical definition of epilepsy. *Epilepsia* 55: 475–82.
- Fleidervish, I.A., Friedman, A., Gutnick, M.J. 1996. Slow inactivation of Na<sup>+</sup> current and slow cumulative spike adaptation in mouse and guinea pig neocortical neurones in slices. *J Physiol* 493: 83–97.
- Fletcher, E.V., Kullmann, D.M., Schorge, S. 2011. Alternative splicing modulates inactivation of type 1 voltage-gated sodium channels by toggling an amino acid in the first S3- S4 linker. *J Biol Chem* 286(42): 36700–36708.
- Ghaem, H., Borhani- Haghighi, A. 2010. Validity and reliability of the Persian epilepsy quality of life questionnaire. *Neurosciences* 15: 249- 253.
- Gherzi-Egea, J.F., Strazielle, N. 2002. Choroid plexus transporters for drugs and other xenobiotics. *J Drug Target* 10: 353-7.
- Gibson, G. 1996. Epistasis and pleiotropy as natural properties of transcriptional regulation. *Theor Popul Biol* 49: 58-89.
- Gilioli, I., Vignoli, A., Visani, E., Casazza, M., Canafoglia, L., Chiesa, V., *et al.*, 2012. Focal epilepsies in adult patients attending two epilepsy centers: classification of drug-resistance, assessment of risk factors, and usefulness of “new” antiepileptic drugs: Pharmacoresistance in Focal Epilepsies. *Epilepsia* 53, 733–740.
- Glauser, T., Ben-Menachem, E., Bourgeois, B., Cnaan, A., Guerreiro, C., Kalviainen, R. 2013. Updated ILAE evidence review of antiepileptic drug efficacy and effectiveness as initial monotherapy for epileptic seizures and syndromes. *Epilepsia* 54: 551–563.
- Guerrini, R. 2006. Epilepsy in children. *Lancet* 367:499–524.
- Gustafson, T.A., Clevinger, E.C., O'Neill, T.J., Yarowsky, P.J., Krueger, B.K. 1993. Mutually exclusive exon splicing of type III brain sodium channel  $\alpha$



- subunit RNA generates developmentally regulated isoforms in rat brain. *J Biol Chem* 268:18648–53.
- Goldenberg, M.M., 2010. Overview of drugs used for epilepsy and seizures: etiology, diagnosis, and treatment. *Pharmacy and Therapeutics*, 35(7), p.392.
- Goldin, A. L. 2003. Mechanisms of sodium channel inactivation. *Curr Opin Neurobiol* 13: 284-290.
- Gorter, J.A., Van Vliet, E.A., Lopes da Silva, F.H., Isom, L.L., Aronica, E. 2002. Sodium channel beta1-subunit expression is increased in reactive astrocytes in a rat model for mesial temporal lobe epilepsy. *Eur J Neurosci* 16:360–364.
- Haerian, B.S., Baum, L., Tan, H.J. 2012. SCN1A IVS5N+5 polymorphism and response to sodium valproate: a multi- center study. *Pharmacogenetics* 13: 1477-1485.
- Haerian, B.S., Baum, L., Kwan, P. 2013. SCN1A, SCN2A and SCN3A gene polymorphisms and responsiveness to antiepileptic drugs: a multicenter cohort study and meta-analysis. *Pharmacogenetics* 14: 1153-1166.
- Hao J, Liu H, Ma J, Liu G, Dong G, Liu P, Xiao F. 2020. SCN1A IVS5N+5 G>A Polymorphism and Risk of Febrile Seizure and Epilepsy: A Systematic Review and Meta-Analysis. *Front Neurol* 11:581539. doi: 10.3389/fneur.2020.581539. PMID: 33391151; PMCID: PMC7773848
- Harms, S.L., Eberly, L.E., Garrard, J.M., Hardie, N.A., Bland, P.C., Leppik, I.E. 2005. Prevalence of appropriate and problematic antiepileptic combination therapy in older people in the nursing home. *J Am Geriatr Soc* 53: 1023-1028.
- Hartshorne, R.P., Catterall, W.A. 1981. Purification of the saxitoxin receptor of the sodium channel from rat brain. *Proc Natl Acad Sci USA* 78:4620–4624.
- Hartshorne, R.P., Catterall, W.A. 1984. The sodium channel from rat brain. Purification and subunit composition. *J Biol Chem* 259:1667–1675.
- Heinzen, E.L., Yoon, W., Tate, S.K., Sen, A., Wood, N.W., Sisodiya, S.M., *et al.*, 2007. Nova2 interacts with a cis-acting polymorphism to influence the proportions of drug-responsive splice variants of SCN1A. *Am J Hum Genet* 80:876–883.
- Herini, E.S., Gunadi, Van Kepen, M.J.A., Yusoff, S., Sunartini *et al.* 2010. Novel *SCN1A* mutations in Indonesian patients with severe myoclonic epilepsy in infancy. *Pediatrics International* 52:234–239.
- Hille, B., 1977. Local anesthetics: hydrophilic and hydrophobic pathways for the



- drug-receptor reaction. *J Gen. Physiol* 69, 497-515.
- Hille, B. 1992. *Ion channels of excitable membranes*. Sinauer Associates Inc. Sunderland, MA.
- Hille B. 2001. *Ion channels of excitable membranes*. 3<sup>rd</sup> ed. Sinauer Associates Inc. Sunderland, MA.
- Hirose, S., Mitsudome, A., Okada, M., Kaneko, S. 2005. Epilepsy Genetic Study Group, Japan. Genetics of idiopathic epilepsies. *Epilepsia* 46 (Suppl): 38-43.
- Hirose, S. 2006. A new paradigm of channelopathy in epilepsy syndromes: intracellular trafficking abnormality of channel molecules. *Epilepsy Res* 70: 206-217.
- Hitiris, N., Mohanraj, R., Norrie, J., Sills, G.J., Brodie, M.J. 2007. Predictors of pharmaco-resistant epilepsy. *Epilepsy Res* 75: 192-196.
- Hodgkin, A.L., Huxley, A.F. 1952a. The dual effect of membrane potential on sodium conductance in the giant axon of *Loligo*. *J Physiol Lond* 116: 497-506.
- Hodgkin, A.L., Huxley, A.F. 1952b. The components of membrane conductance in the giant axon of *Loligo*. *J Physiol Lond* 116: 473-496.
- Hodgkin, A.L., Huxley, A.F. 1952c. Currents carried by sodium and potassium ions through the membrane of the giant axon of *Loligo*. *J Physiol Lond* 116: 473-506.
- Hodgkin, A.L., Huxley, A.F. 1952d. A quantitative description of membrane current and its application to conduction and excitation in nerve. *J Physiol Lond* 117: 500-544.
- Hondeghem, L.M., Katzung, B.G., 1977. Time- and voltage-dependent interactions of antiarrhythmic drugs with cardiac sodium channels. *Biochimica et Biophys Acta* 472: 373-398.
- Hotson, D.A., Prince, P.A., Schwartzkroin. 1979. Anomalous inward rectification in hippocampal neurons. *J Neurophysiol* 42: 889-95.
- Hung, C.C., Chang, W.L., Ho, J.L. 2012. Association of polymorphisms in EPHX1, UGT2B7, ABCB1, ABCC2, SCN1A and SCN2A genes with carbamazepine therapy optimization. *Pharmacogenomics* 13(2):159-169.
- Huguenard, J. R., Hamill, O. P., Prince, A. 1988. Developmental changes in Na<sup>+</sup> conductance in rat cortical neurons: appearance of a slowly inactivating component. *J Neurophysiol* 59: 778-795.

- Hung, C.C., Chang, W.L., Ho, J.L. 2012. Association of polymorphisms in EPHX1, UGT2B7, ABCB1, ABCC2, SCN1A and SCN2A genes with carbamazepine therapy optimization. *Pharmacogenomics* 13: 159-69.
- Iafrate, A.J., Feuk, L., Rivera, M.N., Listewnik, M.L., Donahoe, P.K., Qi, Y. 2004. Detection of large-scale variation in the human genome. *Nat Genet* 36:949-951.
- Iorga, A., Horowitz, B.Z., 2019. Phenytoin Toxicity. In *StatPearls [Internet]*. StatPearls Publishing.
- Isom, L.L. 2002. The role of sodium channels in cell adhesion. *Front Biosci* 7:12-23.
- Isom, L.L., Ragsdale, D.S., De Jongh, K.S., Westenbroek, R.E., Reber, B.F., Scheuer, T. 1995. Structure and function of the beta 2 subunit of brain sodium channels, a transmembrane glycoprotein with a CAM motif. *Cell* 83:433-442.
- Le Gal, F., Salzmann, A., Crespel, A., Malafosse, A. 2011. Replication of association between a SCN1A splice variant and febrile seizures. *Epilepsia*. 52:e135-8.
- Lu, Y., Su, Q., Li, M., Dayimu, A., Dai, X., Wang, Z., et al. 2020. Association of SCN1A, SCN2A, and UGT2B7 polymorphisms with responsiveness to valproic acid in the treatment of epilepsy. *Biomed Res Int*. 2020:8096235.
- Lubis, N.A., Muis, K., Nasution L.H. 2018. Polymerase Chain Reaction-Restriction Fragment Length Polymorphism as a Confirmatory Test for Onychomycosis. *Open Access Macedonian Journal of Medical Sciences* 6(2):280-283.
- Maryam, I.S., Wijayanti, I.A., Tini, K. 2018. Karakteristik pasien epilepsi di poliklinik saraf rumah sakit umum pusat sanglah periode januari-desember 2016. *Callosum Neurology Journal* Volume 1, Nomor 3: 91-96.
- Jang, S.Y., Kim, M.K., Lee, K.R. 2009. Gene-to-gene interaction between sodium channel-related genes in determining the risk of antiepileptic drug resistance. *J Korean Med Sci* 24:62-68.
- Jefferys, J.G.R. 2003. Models and Mechanisms of Experimental Epilepsies. *Epilepsia* 44: 44-50.
- Jimenez-Sanchez, G. 2003. Developing a platform for genomic medicine in Mexico. *Science* 300:295-6.
- Johannessen, S.I., Tomson, T. 2006. Pharmacokinetic variability of newer

- antiepileptic drugs: when is monitoring needed? *Clin Pharmacokinet* 45:1061–1075.
- Jones, G.L., Wimbish, G.H. McIntosh, W.E. 1983. Phenytoin : basic and clinical pharmacology. *Med. Res. Rev.* 3:83
- Joshi, R., Tripathi, M., Gupta, P., Gulati, S., Gupta, Y.K. 2017. Adverse effects & drug load of antiepileptic drugs in patients with epilepsy: Monotherapy versus polytherapy. *Indian J Med Res* 145: 317-326.
- Kalilani, L., Sun, X., Pelgrims, B., Noack-Rink, M., Villanueva, V., 2018. The epidemiology of drug-resistant epilepsy: a systematic review and meta analysis. *Epilepsia* 59, 2179–2193.
- Kalviainen, R., Salmenpera, T. 2002. Do recurrent seizures cause neuronal damage? A series of studies with MRI volumetry in adults with partial epilepsy. *Prog Brain Res* 135: 279-295.
- Kim, M.K., Moore, J.H., Kim, J.K. 2011. Evidence for epistatic interactions in antiepileptic drug resistance. *J Hum Genet* 56:71–76.
- Klee, M.R., Faber, D.S., Heiss, W.D. 1973. Strychnine and pentylentetrazol induced changes of excitability in alypsia neurons. *Science* 179:1133–1136.
- Klotz, U. 2007. The role of pharmacogenetics in the metabolism of antiepileptic drugs: pharmacokinetic and therapeutic implications. *Clin Pharmacokinet* 46:271–279.
- Klugbauer, N., Lacinova, L., Flockerzi, V., Hofmann, F.1995. Structure and functional expression of a new member of the tetrodotoxin- sensitive voltage-activated sodium channel family from human neuroendocrine cells. *EMBO J* 14:1084–1090.
- Kohling, R. 2002. Voltage-gated sodium channels in epilepsy. *Epilepsia* 43: 1278–1295.
- Kumari R, Lakhan R, Kumar S. 2013. SCN1A IVS5- 91G>A polymorphism is associated with susceptibility to epilepsy but not with drug responsiveness. *Biochimie* 95: 1350-3.
- Kuo, C.C. 1998. A common anticonvulsant binding site for phenytoin, carbamazepine, and lamotrigine in neuronal Na<sup>+</sup> channels. *Mol Pharmacol.* 54:712–721.
- Kuo, C.C., Lu, L. 1997. Characterization of lamotrigine inhibition of Na<sup>+</sup> channels in rat hippocampal neurones. *Br J Pharmacol.* 121:1231–1238.

- Kuo, C.C., Chen, R.S., Lu, L., Chen, R.C. 1997. Carbamazepine inhibition of neuronal Na<sup>+</sup> currents: quantitative distinction from phenytoin and possible therapeutic implications. *Mol Pharmacol* 51:1077–1083.
- Kuo, C.C., Bean, B.P. 1994. Slow binding of phenytoin to inactivated sodium channels in rat hippocampal neurons. *Mol Pharmacol* 46:716–725.
- Kwan, P., Brodie, M.J. 2000a. Epilepsy after First Drug Fails: Substitution or Add-On. *Seizure* 9: 464-468.
- Kwan, P., Brodie, M. J. 2000b. Early identification of refractory epilepsy. *N Engl J Med* 342:314–319.
- Kwan, P., Brodie, M.J. 2001. Effectiveness of first antiepileptic drug. *Epilepsia* 42:1255-1260.
- Kwan, P., Brodie, M. J. 2002. Refractory epilepsy: a progressive, intractable but preventable condition. *Seizure* 11: 77-84.
- Kwan, P., Baum, L., Wong, V., Ng, P.W., Lui, C.H., Sin, N.C. 2007. Association between *ABCB1* C3435T polymorphism and drug-resistant epilepsy in Han Chinese. *Epilepsy Behav* 11:112-117.
- Kwan, P., Poon, W.S., Ng, H.K., Kang, D.E., Wong, V., Ng, P.W., *et al.*, 2008. Multidrug resistance in epilepsy and polymorphisms in the voltage-gated sodium channel genes *SCN1A*, *SCN2A*, and *SCN3A*: correlation among phenotype, genotype, and mRNA expression. *Pharmacogenet Genomics* 18: 989–998.
- Kwan, P., Arzimanoglou, A., Berg, A.T. 2010. Definition of drug resistant epilepsy: consensus proposal by the *ad hoc* Task Force of the ILAE Commission on Therapeutic Strategies. *Epilepsia* 51(6): 1069–1077.
- Kwong, K.L., Sung, W.Y., Wong, S.N., *et al.* 2003. Early predictors of medical intractability in childhood epilepsy. *Pediatr Neurol* 29:46–52.
- Lahti, J.L., Tang, G.W., Capriotti, T.L., Liu, T., Altman, R.B. 2012. Bioinformatics and variability in drug response: a protein structural perspective. *J R Soc Interface* 9: 1409-1437.
- Lakhan, R., Kumari, R., Misra, U.K., Kalita, J., Pradhan, S., Mittal, B. 2009. Differential role of sodium channels SCN1A and SCN2A gene polymorphisms with epilepsy and multiple drug resistance in north Indian population. *Br J Clin Pharmacol* 68:214-20.
- LaMorte, W.W. 2016. Confounding and Effect Measure Modification. MPH Online

- Learning Module, Boston University School of Public Health. Available at [http://sphweb.bumc.bu.edu/otlt/MPH-Modules/BS/BS704-EP713\\_Confounding-EM/BS704-EP713\\_Confounding-EM3.html](http://sphweb.bumc.bu.edu/otlt/MPH-Modules/BS/BS704-EP713_Confounding-EM/BS704-EP713_Confounding-EM3.html).
- Lazarowski, A., Massaro, M., Schteinschnaider, A., Intruvini, S., Seveler, G., Rabinowicz, A. 2002. Neuronal MDR-1 gene expression and persistent low levels of anticonvulsants in a child with refractory epilepsy. *Ther Drug Monit* 26: 44–46.
- Lee, C.R., Goldstein, J.A., Pieper, J.A. 2002. Cytochrome P450 2C9 polymorphisms: a comprehensive review of the in-vitro and human data. *Pharmacogenetics* 12: 251–263.
- Lemeshow S, Hosmer D, Klar J, Lwanga S. 1990. *Adequacy of sample size in health studies*. John Wiley & Sons.
- Llinas, R., Sugimori, M. 1980. Electrophysiological properties of in vitro Purkinje cell somata in mammalian cerebellar slices. *J Physiol* 305:197–213.
- Lombardo, A.J., Kuzniecky, R., Powers, R.E., Brown, G.B. 1996. Altered brain sodium channel transcript levels in human epilepsy. *Brain Res Mol Brain Res* 35: 84–90.
- Lopez-Garcia, M.A., Feria-Romero, I.A., Fernando-Serrano, H., Escalante-Santiago, D., Grijalva, I., Orozco-Suarez, S. 2014. Genetic polymorphisms associated with antiepileptic metabolism. *Front. Biosci* 6: 77–386.
- Löscher, W., Schmidt, D. 2006. Experimental and clinical evidence for loss of effect (tolerance) during prolonged treatment with antiepileptic drugs. *Epilepsia* 47:1253-84.
- Loscher, W., Klotz, U., Zimprich, F., Schmidt, D. 2009. The clinical impact of pharmacogenetics on the treatment of epilepsy. *Epilepsia* 50: 1-23.
- Lossin, C., Wang, D.W., Rhodes, T.H., Vanoye, C.G., George Jr, A.L. 2002. Molecular basis of an inherited epilepsy. *Neuron* 34:877–84.
- Lossin, C., Rhodes, T.H., Desai, R.R., Vanoye, C.G., Wang, D., Carniciu, S. 2003. Epilepsy-associated dysfunction in the voltage-gated neuronal sodium channel SCN1A. *J Neurosci* 23: 11289–95.
- Lossin, C. A. 2009. Catalog of SCN1A variants. *Brain Dev* 31: 114-30.
- Ma, C.L., Wu, X.Y., Zheng, J., Wu, Z.Y., Hong, Z., Zhong, M.K. 2014. Association of SCN1A, SCN2A and ABCC2 gene polymorphisms with the response to antiepileptic drugs in Chinese Han patients with epilepsy. *Pharmacogenomics*

15(10):1323–1336.

- Macdonald, R.L., Kelly, K.M., 1994. Mechanisms of action of currently prescribed and newly developed antiepileptic drugs. *Epilepsia* 35(4): 41-50.
- Malo, M.S., Blanchard, B.J., Andresen, J.M., Srivastava, K., Chen, X.N., Li, X. 1994. Localization of a putative human brain sodium channel gene (SCN1A) to chromosome band 2q24. *Cytogenet Cell Genet* 67:178–86.
- Malueka, R.G., Theresia, E., Fitria, F., Argo, I.W., Donurizki, A.D., Shaleh, S. *et al.*, 2020. Comparison of Polymerase Chain Reaction-Restriction Fragment Length Polymorphism, Immunohistochemistry, and DNA Sequencing for the Detection of IDH1 Mutations in Gliomas. *Asian Pacific Journal of Cancer Prevention* Vol 21:3229-34.
- Mann, M.W., Pons, G. 2008. Drug resistance in partial epilepsy: Epidemiology, mechanisms, pharmacogenetics and therapeutical aspects. *Neurochirurgie* 54:259-64.
- Manna, I., Labate, A., Borzi, G., Mumoli, L., Cavalli, S.M., Sturniolo, M., Quattrone, A., Gambardella, A. 2016. An SNP site in pri-miR-124, a brain expressed miRNA gene, no contribution to mesial temporal lobe epilepsy in an Italian sample. *Neurol Sci* 37(8):1335–1339.
- Manna, I., Gambardella, A., Bianchi, A., Striano, P., Tozzi, R, Aguglia, U., *et al.*, 2011. A functional polymorphism in the SCN1A gene does not influence antiepileptic drug responsiveness in Italian patients with focal epilepsy. *Epilepsia* 52(5):e40–e44.
- Mantegazza, M., Curia, G., Biagini, G., Ragsdale, D.S., Avoli, M. 2010. Voltage-gated sodium channels as therapeutic targets in epilepsy and other neurological disorders. *Lancet Neurol* 9(4):413–424.
- Matlin, A.J., Clark, F., Smith, C.W. 2005. Understanding alternative splicing: towards a cellular code. *Nat Rev Mol Cell Biol* 6:386–398.
- Meldrum, B.S., Rogawski, M.A. 2007. Molecular targets for antiepileptic drug development. *Neurotherapeutics* 4: 18-61.
- McCollum, I.J., Vilin, Y.Y., Spackman, E., Fujimoto, E., Ruben, P.C., 2003. Negatively charged residues adjacent to IFM motif in the DIII-DIV linker of Na(V)1.4 differentially affect slow inactivation. *FEBS Lett* 552: 163-169.
- McCorry, D., Chadwick, D., Marson, A. 2004. Current drug treatment of epilepsy in adults. *Lancet Neurol* 3:729-35.

- McEwen, D.P., Meadows, L.S., Chen, C., Thyagarajan, V., Isom, L.L. 2004. Sodium channel beta1 subunit-mediated modulation of Nav1.2 currents and cell surface density is dependent on interactions with contactin and ankyrin. *J Biol Chem* 279:16044–16049.
- McPhee, J.C., Ragsdale, D.S., Scheuer, T., Catterall, W.A., 1994. A mutation in segment IVS6 disrupts fast inactivation of sodium channels. *Proc Natl Acad Sci USA* 91: 12346-12350.
- McPhee, J.C., Ragsdale, D.S., Scheuer, T., Catterall, W.A. 1995. A critical role for transmembrane segment IVS6 of the sodium channelsubunit in fast inactivation. *J Biol Chem* 270: 12025-12034.
- McPhee, J.C., Ragsdale, D.S., Scheuer, T., Catterall, W.A., 1998. A critical role for the S4eS5 intracellular loop in domain IV of the sodium channel alpha-subunit in fast inactivation. *J Biol Chem* 273: 1121-1129.
- Meadows, L.S., Malhotra, J., Loukas, A., Thyagarajan, V., Kazen-Gillespie, K.A., Koopman, M.C. 2002. Functional and biochemical analysis of a sodium channel beta1 subunit mutation responsible for generalized epilepsy with febrile seizures plus type 1. *J Neurosci* 22:10699–709.
- Meisler, M.H., Kearney, J.A. 2005. Sodium channel mutations in epilepsy and other neurological disorders. *J Clin Invest* 115: 2010–7.
- Mohanraj, R., Brodie, M.J. 2006. Diagnosing refractory epilepsy: response to sequential treatment schedules. *Eur J Neurol* 13:277–282.
- Morisky, D.E., DiMatteo, M.R. 2011. The morisky 8-item self-report measure of medication-taking behavior (MMAS-8). *J. Clin. Epidemiol.* 64: 262-263.
- Moshe, S.L. 2000. Mechanisms of action of anticonvulsant agents. *Neurology* 55:32-40.
- Murphy, B. J., Li, M., West, J. W., Numann, R., Scheuer, T., Catterall, W. A. 1993. Convergent regulation of sodium channels by protein kinase C and cAMP-dependent protein kinase. *Science* 261: 1439–1442.
- Namazi, S., Azarpira, N., Javidnia, K. 2015. SCN1A and SCN1B gene polymorphisms and their association with plasma concentrations of carbamazepine and carbamazepine 10, 11 epoxide in Iranian epileptic patients. *Iran J Basic Med Sci* 18:1215– 1220.
- Nazish, H.M., Ali, N., Ullah, S. 2018. The possible effect of SCN1A and SCN2A genetic variants on carbamazepine response among Khyber Pakhtunkhwa epileptic patients, Pakistan. *Therapeutics and Clinical Risk Management*



14:2305–2313.

- Narahashi, T. 1982. Cellular and molecular mechanisms of action of insecticides: neurophysiological approach. *Neurobehav Toxicol* 4:753–758.
- Naritoku, D.K., Hulihan, J.F., Schwarzman, L.K., Kamin, M., Olson, W.H. 2005. Effect of cotherapy reduction on tolerability of epilepsy add-on therapy: a randomized controlled trial. *Ann Pharmacother* 39: 418-423.
- Neuvonen, P.J., 1979. Bioavailability of phenytoin: clinical pharmacokinetic and therapeutic implications. *Clinical pharmacokinetics*, 4(2), pp.91-103.
- Novak, P.H., Ekins-Daukes, S., Simpson, C.R., Milne, R.M., Helms, P., McLay, J.S. 2005. Acute drug prescribing to children on chronic antiepilepsy therapy and the potential for adverse drug interactions in primary care. *Br J Clin Pharmacol* 59(6): 712-717.
- Yolanda, N.G.A., Sarehart, T.P., Istiadi H. 2019. *Jurnal Kedokteran Diponegoro*. Volume 8, Nomor 1, Online : <http://ejournal3.undip.ac.id/index.php/medico> ISSN Online : 2540-8844.
- Onkal, R., Mattis, J.H., Fraser, S.P., Diss, J.K., Shao, D., Okuse, K., *et al.*, Alternative splicing of Nav1.5: an electrophysiological comparison of ‘neonatal’ and ‘adult’ isoforms and critical involvement of a lysine residue. *J Cell Physiol* 216:716–726.
- Osaka, H., Ogiwara, I., Mazaki, E. 2007. Patients with a sodium channel  $\alpha 1$  gene mutation show wide phenotypic variation. *Epilepsy Res* 75: 46–51.
- Oskoui, M., Webster, R.I., Zhang, Xun, Shevell, M.I., 2005. Factors predictive of outcome in childhood epilepsy. *J. Child Neurol.* 20, 898–904.
- Panayiotopoulos, C.P., Ferrie, C.D., Knott, C. 1993. Interaction of lamotrigine with sodium valproate [letter]. *Lancet* 341: 445.
- Panayiotopoulos. 2005. The Epilepsies Seizures, Syndromes and Management. UK: *Bladon Medical Publishing* 128-36.
- Patlak, J., Horn, R. 1982. Effect of N-bromoacetamide on single sodium channel currents in excised membrane patches. *J Gen Physiol* 79:333–351.
- Patton, D.E., Isom, L.L., Catterall, W.A., Goldin, A.L. 1994. The adult rat brain beta 1 subunit modifies activation and inactivation gating of multiple sodium channel  $\alpha$  subunits. *J Biol Chem* 269:17649–17655.
- Patton, D.E., West, J. W., Catterall, W.A., Goldin, A.L. 1992. Amino acid residues

- required for fast Na<sup>+</sup> channel inactivation: charge neutralizations and deletions in the III-IV linker. *Proc Nat Acad Sci U.S.A.* 89:10905-109019.
- Payandeh, J., Scheuer, T., Zheng, N. 2011. The crystal structure of a voltage-gated sodium channel. *Nature* 475: 353–358.
- Perucca, E. 1996. Established Antiepileptic Drugs. *Baillieres clin Neurol.* 5:693-722.
- Petrovski, S., Scheffer, I.E., Sisodiya, S.M., *et al.*, 2009. Lack of replication of association between scn1a SNP and febrile seizures. *Neurology.* 73:1928–30.
- Piana, C., Antunes, N. J., Pasqua, O. 2014. Implications of pharmacogenetics for the therapeutic use of antiepileptic drugs. *Expert Opin Drug Metab Toxicol* 10:341–358.
- Plummer, N.W., Meisler, M.H. 1999 Evolution and diversity of mammalian sodium channel genes. *Genomics* 57:323–331.
- Pomeroy, L.S. Holmes, S.J., Dodge, P.R., Feign, R.D. 1990. Seizures and other neurologic sequelae of bacterial meningitis in children. *N Engl J Med* 323: 1651-1657.
- Potschka, H., Brodie, M.J. 2012. Pharmacoresistance. *Handb Clin Neurol* 108: 741–757.
- Qian, L., Fang, S., Yan, Y.L., Zeng, S.S., Xu, Z.J., Gong, Z.C. 2017. The ABCC2 C.-24C>T polymorphism increases the risk of resistance to antiepileptic drugs: a meta-analysis. *J Clin Neurosci* 37:6–14.
- Qu, J., Zhou, B.T., Yin, J.Y., Xu, X.J., Zhao, Y.C., Lei, G.H, *et al.*, 2012. ABCC2 polymorphisms and haplotype are associated with drug resistance in Chinese epileptic patients. *CNS Neurosci Ther.* 18(8):647–51.
- Ragsdale, D.S., Scheuer, T., Catterall, W.A.1991. Frequency and voltage-dependent inhibition of type IIA Na<sup>+</sup> channels, expressed in a mammalian cell line, by local anesthetic, antiarrhythmic, and anticonvulsant drugs. *Mol Pharmacol.* 40:756–765.
- Ragsdale, D.S., Avoli, M. 1998. Sodium channels as molecular targets for antiepileptic drugs. *Brain Res Brain Res Rev* 26: 16–28.
- Ramachandran, V., Shorvon, S.D. 2003. Clues to the genetic influences of drug responsiveness in epilepsy. *Epilepsia* 44:33-37.
- Raman, I.M., Sprunger, L.K., Meisler, M.H. 1997. Altered subthreshold sodium

currents and disrupted firing patterns in Purkinje neurons of SCN8a mutant mice. *Neuron* 19:881–891.

Rambeck, B., May, T., Juergens, U. 1987. Serum concentrations of carbamazepine and its epoxide and diol metabolites in epileptic patients: the influence of dose and comedication. *Ther Drug Monit* 9:298–303.

Regesta, G., Tanganelli, P. 1999. Clinical aspects and biological bases of drug-resistant epilepsies. *Epilepsy Res* 34: 109–122.

Remy, S., Gabriel, S., Urban, B.W., Dietrich, D., Lehmann, T.N., Elger, C.E. 2003. A novel mechanism underlying drug resistance in chronic epilepsy. *Ann Neurol* 53:469–479.

Remy, S., Beck, H. 2006. Molecular and cellular mechanisms of pharmacoresistance in epilepsy. *Brain* 129:18–35.

Reynolds, E.H. Elwes, R.D.C., Shorvon, S.D. 1983. Why does epilepsy become intractable? Prevention of chronic epilepsy. *Lancet* 322: 952-954.

Reynolds, E.H. Shorvon, S.D. 1981a. Monotherapy or polytherapy for epilepsy. *Epilepsia*. 22: 1-10.

Reynolds, E.H. Shorvon, S.D. 1981b. Single drug or combination therapy for epilepsy. *Drugs*. 21: 474-482.

Richens, A., 1979. Clinical pharmacokinetics of phenytoin. *Clinical pharmacokinetics*, 4(3), pp.153-169.

Richmond, J.E., Featherstone, I.A., Hartmann, H.A., Ruben, P.C. 1998. Slow inactivation in human cardiac sodium channels. *Biophys J* 74: 2945-52.

Ritchie, M.D., Hahn, L.W., Roodi, N., Bailey, L.R., Dupont, W.D., Parl, F.F., *et al.*, 2001. Multifactor-dimensionality reduction reveals high-order interactions among estrogen-metabolism genes in sporadic breast cancer. *Am J Hum Genet* 69: 138-47.

Roden, D.M., George Jr, A.L., Bennett, P.B. 1995. Recent advances in understanding the molecular mechanisms of the long QT syndrome. *J Cardiovasc Electrophysiol* 6:1023–31.

Rogawski, M.A., Loscher, W. 2004. The neurobiology of antiepileptic drugs. *Nat Rev Neurosci* 5: 553–64.

Roy P.L., Ronquillo L.H., Ladino L.D., Tellez-Zenteno J.F. 2019. Risk factors associated with drug resistant focal epilepsy in adults: a case control study. *Seizure*. 73:46–50. doi:10.1016/j.seizure.2019.10.020

- Rugg-Gunn, F.J. 2015. Adult onset epilepsies. Department of Clinical and Experimental Epilepsy, National Hospital for Neurology and Neurosurgery, Queen Square, London. <https://www.epilepsysociety.org.uk/sites/default/files/attachments/Chapter12Rugg-Gunn2015>.
- Sanchez, M.B., Herranz, J.L., Leno, C., Arteaga, R., Oterino, A., Valdizán, E.M. 2010. Genetic factors associated with drug-resistance of epilepsy: relevance of stratification by patient age and aetiology of epilepsy. *Seizure* 19:93–101.
- Santoso B. Genetic and environmental influences on polymorphic drug acetylation. Newcastle upon Tyne (dissertation): University of Newcastle upon Tyne, 1983.
- Sarao, R., Gupta, S.K., Auld, V.J., Dunn, R.J. 1991. Developmentally regulated alternative RNA splicing of rat brain sodium channel mRNAs. *Nucleic Acids Res* 19:5673–5679.
- Saygi, S., Erol, I., Alehan, F. 2014. Early clinical predictors of intractable epilepsy in childhood. *Turk J Med Sci* 44:490–5.
- Schmidt., D. 1979. One drug treatment with phenytoin in difficult to treat epilepsies with complex partial seizures: a preliminary report of a prospective study; in Johannessen (Eds) *Antiepileptic Therapy: Advances in Drug Monitoring*. pp.221-228.
- Schmidt, D., Kramer, G. 1994. The new anticonvulsant drugs: implications for avoidance of adverse effects. *Drug Saf* 2: 422-423.
- Schiller, Y., Najjar, Y. 2008. Quantifying the response to antiepileptic drugs: effect of past treatment history. *Neurology* 70: 54–65.
- Semah, F. Picot, M.C.Adam, C., Broglin, P. Arzimanoglou, A. Brazin, B., Cavalcanti, D. Baulac, M. 1998. Is the underlying cause of epilepsy a major prognostic factor for recurrence?. *Neurol* 51(5): 1256-1262.
- Shah, M.M., Anderson, A.E., Leung, V., Lin, X., Johnston, D. 2004. Seizure-induced plasticity of h channels in entorhinal cortical layer III pyramidal neurons. *Neuron* 244: 495–508.
- Shorvon, S.D. 2010. Handbook of epilepsy treatment. *John Wiley and Sons*:London.
- Siep, E., Richter, A., Speckmann, E.J. 2000. Sodium currents in striatal neurons from dystonic hamsters. *Soc Neurosci Abstr* 26: 572.18.

- Siep, E., Richter, A., Löscher, W. 2002. Sodium currents in striatal neurons from dystonic hamsters: altered response to lamotrigine. *Neurobiol Dis* 9:258–268.
- Sillanpaa, M., Jalava, M., Kaleva, O., Shinnar, S. 1998. Long-term prognosis of seizures with onset in childhood. *N Engl J Med* 338:1715–1722.
- Sills, G.J., Mohanraj, R., Butler, E., McCrindle, S., Collier, L., Wilson, E.A. 2005. Lack of association between the C3435T polymorphism in the human multidrug resistance (MDR1) gene and response to antiepileptic drug treatment. *Epilepsia* 246:643–647.
- Silvado, C.E., Terra, V.C. and Twardowschy, C.A., 2018. CYP2C9 polymorphisms in epilepsy: influence on phenytoin treatment. *Pharmacogenomics and personalized medicine*, 11, p.51.
- Silverman, I.E., Restrepo, L., Mathews, G.C. 2002. Poststroke seizures. *Arch Neurol* 59: 195–201.
- Sisodiya, S.M. 2005. Genetics of drug resistance. *Epilepsia*, 46(Suppl 10): 33–38.
- Sisodiya, S.M., Marini, C. 2009. Genetics of antiepileptic drug resistance. *Curr Opin Neurol* 22(2):150–156.
- Smith M.D., Metcalf C.S., Wilcox K.S. 2018. Pharmacotherapy of the epilepsies. In, Brunton LL, Hilal-Dandan R, Knollman BC, eds. *Goodman & Gilman's the pharmacological basis of therapeutics*. 13th ed. New York: McGraw-Hill, pp. 303–26.
- Smith, R.D., Goldin, A.L. 1996. Phosphorylation of brain sodium channels in the I-II linker modulates function in *Xenopus* oocytes. *J Neurosci* 16:1965–1974.
- Spampanato, J., Kearney, J.A., De Haan, G., McEwen, D.P., Escayg, A., Aradi, I. 2004. A novel epilepsy mutation in the sodium channel SCN1A identifies a cytoplasmic domain for beta subunit inter- action. *J Neurosci* 24:10022–10034.
- Speckmann, E.J., Caspers, H. 1978. Effects of pentylenetetrazol on isolated snail and mammalian neurons. In: Chalazonitis N, Boisson N, eds. *Abnormal neuronal discharges*. 165–176.
- Sporis, D., Bozina, N., Basic, S. 2013. Lack of association between polymorphism in ABCC2 gene and response to antiepileptic drug treatment in Croatian patients with epilepsy. *Coll Antropol* 37:41–45.
- Spruston, N., Schiller, Y., Stuart, G. 1995. Activity-dependent action potential invasion and calcium influx into hippocampal CA1 dendrites. *Science* 268:297–300.

- Stafstrom, C.E., Schwindt, P.C., Crill, W.E. 1982. Negative slope conductance due to a persistent subthreshold sodium current in cat neocortical neurons *in vitro*. *Brain Res.* 236: 221-226.
- Stafstrom, C.E., Schwindt, P.C., Chubb, M.C., Crill, W.E. 1985. Properties of persistent sodium conductance and calcium conductance of layer V neurons from cat sensorimotor cortex *in vitro*. *J. Neurophysiol.* 53:152-170.
- Sterjev, Z., Kiteva, G., Cvetkovska, E., Petrov, I., Kuzmanovski, I., Ribarska, T., *et al.*, 2012 Influence of the SCN1A IVS5N + 5 G>A Polymorphism on Therapy with Carbamazepine for Epilepsy. *Balkan J Med Genet* 15(1):19–24
- Stümer, W., Conti, F., Suzuki, X., Wang, M., Noda, M., Yahadi, N., Kubo, H., Numa, S. 1989. Structural parts involved in activation and inactivation of the voltage gated sodium channel. *Nature* 339: 597-603.
- St. Louis, E.K. 2009. Truly “Rational” Polytherapy: maximizing efficacy and minimizing drug interactions, drug load, and adverse effects. *Current Neuropsychopharmacology* 7: 96-105.
- St. Louis, E.K., Gidal, B.E., Henry, T.R., Kaydanova, Y., Krumholz, A., McCabe, P.H., *et al.*, 2007. Conversions between monotherapies in epilepsy: expert consensus. *Epilepsy Behav* 11: 222-234.
- St. Louis, E.K., Rosenfeld, W.E., Bramley, T. 2009. Antiepileptic drug monotherapy: The initial approach in epilepsy. *Curr Neuropsychopharmacol* 7: 77-82.
- Sutarni, S. 2004. Neuropati Akibat Paparan Fenitrothion pada Peneyemprot Malaria. Disertasi. Universitas Gadjah Mada.
- Szoeke, C.E., Newton, M., Wood, J.M., Goldstein, D., Berkovic, S.F., O'Brien, T.J. 2006. Update on pharmacogenetics in epilepsy: A brief review. *Lancet Neurol* 5:189-96.
- Tan, J., Liu, Z., Nomura, Y., Goldin, A.L., Dong, K. 2002. Alternative splicing of an insect sodium channel gene generates pharmacologically distinct sodium channels. *J Neurosci.* 22:5300–5309.
- Tan, N.C., Berkovic, S.F. 2010. The Epilepsy Genetic Association Database (epiGAD): analysis of 165 genetic association studies, 1996-2008. *Epilepsia* 51:686–689.
- Tang, L., Lu, X., Tao, Y. 2014. SCN1A rs3812718 polymorphism and susceptibility to epilepsy with febrile seizures: a meta-analysis. *Gene* 533: 26-31.

- Tate, S.K., Depondt, C., Sisodiya, S.M., Cavalleri, G.L., Schorge, S., Soranzo, N., *et al.*, 2005. Genetic predictors of the maximum doses patients receive during clinical use of the anti-epileptic drugs carbamazepine and phenytoin. *Proc Natl Acad Sci USA* 102: 5507–5512.
- Tate, S.K., Singh, R., Hung, C.C., Tai, J.J., Depondt, C., Cavalleri, G.L., *et al.*, 2006. A common polymorphism in the *SCN1A* gene associates with phenytoin serum levels at maintenance dose. *Pharmacogenet Genomics* 16: 721–726.
- Tatro, D.S. 2003. *A to Z Drug Facts*. San Fransisco : Facts and Comparisons.
- Taylor, C.P. 1993. Na<sup>+</sup> currents that fail to inactivate. *Trends Neurosci.* 16:455-460.
- Thomas SV, Koshy S, Sudhakaran Nair C R, Sarma SP. 2005. Frequent seizures and polytherapy can impair quality of life in persons with epilepsy. *Neurol India* 53:46-50.
- Thompson, C.H., Kahlig, K.M., George, A.L.Jr. 2011. SCN1A splice variants exhibit divergent sensitivity to commonly used antiepileptic drugs. *Epilepsia* 52:1000- 1009.
- Tian, L.M., Ootom, S., Alkadhi, K.A. 1995. Endogenous bursting due to altered sodium channel function in rat hippocampal CA1 neurons. *Brain Res* 680:164–172.
- Toib, A., Lyakhov, V., Marom, S. 1998. Interaction between duration of activity and time course of recovery from slow inactivation in mammalian brain Na<sup>+</sup> channels. *J Neurosci* 18: 1893-1903.
- Toledo-Aral, J.J., Moss, B.L., He, Z.J., Koszowski, A.G., Whisenand, T., Levinson, S.R. 1997. Identification of PN1, a predominant voltage- dependent sodium channel expressed principally in peripheral neurons. *Proc Natl Acad Sci USA* 94:1527–1532.
- Traub, R.D., Borck, C., Colling, S.B., Jefferys, J.G. 1996. On the structure of ictal events *in vitro*. *Epilepsia* 37: 879-891.
- Traub, R.D., Jefferys, G.R., Whittington, M.A. 1999. Fast Oscillations in Cortical Circuits. *The MIT Press*: Cambridge, MA.
- Trimmer, J.S., Rhodes, K.J. 2004. Localization of voltage-gated ion channels in mammalian brain. *Annu Rev Physiol* 66:477–519.
- Tripathi, K.D. 2013. *Essential of Medical Pharmacology 7<sup>th</sup> Edition*. Jaypee Brothers Medical Publisher. New Delhi.



- Ule, J., Ule, A., Spencer, J., Williams, A., Hu, J.S., Cline, M., Wang, H., Clark, T., Fraser, C., Ruggiu, M. 2005. Nova regulates brain- specific splicing to shape the synapse. *Nat Genet* 37:844–852
- Vassilev, P.M., Scheuer, T., Catterall, W.A. 1988. Identification of an intracellular peptide segment involved in sodium channel inactivation. *Science* 241:1658-61.
- Vassilev, P., Scheuer, T., Catterall, W.A. 1989. Inhibition of inactivation of single sodium channels by a site-directed antibody. *Proc Natl Acad Sci* 86:8147–8151.
- Vilin, Y.Y., Ruben, P.C. 2001. Slow inactivation in voltage-gated sodium channels: molecular substrates and contributions to channelopathies. *Cell Biochem Biophys* 35: 171–190.
- Walker, M.C. 2006. Rational Polypharmacy: Which Combinations are Most Likely to Lead to Seizure Freedom? In: Trimble MR, editor. *Seizure Freedom: Clinical, Research and Quality of Life Perspectives*. p. 55-73.
- Wang, P., Zhou, Q., Sheng, Y., Tang, B., Liu, Z., Zhou, B. 2014. Association between two functional SNPs of SCN1A gene and efficacy of carbamazepine monotherapy for focal seizures in Chinese Han epileptic patients. *J Cent S Univ Med Sci* 39(5): 433–441.
- West, J.W., Patton, D.E., Scheuer, T., Wang, Y., Goldin, A.L., Catterall, W.A. 1992. A cluster of hydrophobic amino acid residues required for fast Na<sup>+</sup> channel inactivation. *Proc Nat Acad Sci USA* 89: 10910-10914.
- Wibowo S, Chuseiri A, Aswin S, Santosa B. 1999. Hubungan Status Asetilasi dengan terjadinya neuropati otonom. Kajian kasus neuropati diabetika. *Berkala Ilmu Kedokteran* (37): 2:99-104.
- Williams, S.M., Ritchie, M.D., Phillips, J.A. 3rd., Dawson, E., Prince, M., Dzhura, E., *et al.*, 2004. Multilocus analysis of hypertension: a hierarchical approach. *Hum Hered* 57: 28-38.
- Wilson, J.F., Weale, M.E., Smith, A.C., Gratrix, F., Fletcher, B. 2001. Population genetic structure of variable drug response. *Nat Genet* 29:265-269.
- Wright, J., Pickard, N., Whitfield, A., Hakin, N. 2000. A population- based study of the prevalence, clinical characteristics and effect of ethnicity in epilepsy. *Seizure* 9(5): 309–313.
- Xie, X., Dale, T.J., John, V.H., Cater, H.L., Peakman, T.C., Clare, J.J. 2001. Electrophysiological and pharmacological properties of the human brain type IIA Na<sup>+</sup> channel expressed in a stable mammalian cell line. *Pflugers Arch* 441:

425–433.

Xue-Ping, W., Hai-Jiao, W., Li-Na, Z., Xu, D., Ling, L. 2019. Risk factors for drug-resistant epilepsy. *Medicine* vol. 98, no. 30, pp. e16402–e16412.

Yang, Y.C., Kuo, C.C. 2002. Inhibition of Na(+) current by imipramine and related compounds: different binding kinetics as an inactivation stabilizer and as an open channel blocker. *Mol Pharmacol* 62:1228–1237.

Yip, O'Doherty C, Tan NCK. 2014. SCN1A variations and response to multiple antiepileptic drugs. *Pharmacogenomics* 14: 385-389

Yu, F.H., Catterall, W.A. 2004. The VGL-chnome: A protein superfamily specialized for electrical signaling and ionic homeostasis. *Sci STKE* 253: re 15.

Yun, W., Zhang F., Hu, C., Luo, X., Xue, P., Wang J., *et al.*, 2013 Effects of EPHX1, SCN1A and CYP3A4 genetic polymorphisms on plasma carbamazepine concentrations and pharmacoresistance in Chinese patients with epilepsy. *Epilepsy Res* 107(3):231–237.

Zelano, J. 2016. Poststroke epilepsy: update and future directions. *Ther Adv Neurol Disord* 9(5) 424–435.

Zelano, J. Lundberg, R.G., Baars, L. Hedegard, E. Kumlien, E. 2015. Clinical course of poststroke epilepsy: a retrospective nested case–control study. *Brain Behav* 5(9): e00366.

Zhang, M.Q. 1998. Statistical features of human exons and their flanking regions. *Hum Mol Genet* 7:919–932.

Zhou, B.T., Zhou, Q.H., Yin, J.Y. 2012. Comprehensive analysis of the association of SCN1A gene polymorphisms with the retention rate of carbamazepine following mono- therapy for new-onset focal seizures in the Chinese Han population. *Clin Exp Pharmacol Physiol* 39: 379-84.

Zimprich, F., Stogmann, E., Bonelli, S. 2008. A functional polymorphism in the SCN1A gene is not associated with carbamazepine dosages in Austrian patients with epilepsy. *Epilepsia* 49: 1108-9.

Zuliani, V., Fantini, M., Rivara, M. 2012. Sodium channel blockers as therapeutic target for treating epilepsy: recent updates. *Curr Top Med Chem* 12(9):962–970.